trending Market Intelligence /marketintelligence/en/news-insights/trending/6NzYWnp0AOJcREpmp_9RZw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Presbia prices rights offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Presbia prices rights offering

Ophthalmic device company Presbia PLC priced its rights offering of 4.5 million ordinary shares at a subscription price per whole share of $3.00.

Under the rights offering, Presbia plans to distribute, at no charge, 0.335297256 subscription right per ordinary share owned on Feb. 6. Shares should be acquired by Feb. 1 to be considered a shareholder of record on Feb. 6.

Holders who exercise their subscription rights in full could subscribe for additional ordinary shares not purchased by other shareholders.

The subscription rights are nontransferable, nontradeable and may only be exercised during the anticipated subscription period of Feb. 7 to Feb. 23, unless extended.

Presbia plans to use net proceeds for general corporate purposes, including funding its U.S. staged pivotal trial for its Flexivue Microlens and Microlens inserter, funding its commercialization efforts, research and development activities related to the microlens inserter, product manufacturing, and acquisitions or investments in businesses, products or technologies.